Literature DB >> 17550503

Translabyrinthine surgery for disabling vertigo in vestibular schwannoma patients.

W P Godefroy1, D Hastan, A G L van der Mey.   

Abstract

OBJECTIVE: To determine the impact of translabyrinthine surgery on the quality of life in vestibular schwannoma patients with rotatory vertigo. STUDY
DESIGN: Prospective study in 18 vestibular schwannoma patients.
SETTING: The study was conducted in a multispecialty tertiary care clinic. PARTICIPANTS: All 18 patients had a unilateral intracanalicular vestibular schwannoma, without serviceable hearing in the affected ear and severely handicapped by attacks of rotatory vertigo and constant dizziness. Despite an initial conservative treatment, extensive vestibular rehabilitation exercises, translabyrinthine surgery was performed because of the disabling character of the vertigo, which considerably continued to affect the patients' quality of life. MAIN OUTCOME MEASURES: Preoperative and postoperative quality of life using the Short Form 36 Health Survey (Short Form-36) scores and Dizziness Handicap Inventory (DHI) scores.
RESULTS: A total of 17 patients (94%) completed the questionnaire preoperatively and 3 and 12 months postoperatively. All Short Form-36 scales of the studied patients scored significantly lower when compared with the healthy Dutch control sample (P < 0.05). There was a significant improvement of DHI total scores and Short Form-36 scales on physical and social functioning, role-physical functioning, role-emotional functioning, mental health and general health at 12 months after surgery when compared with preoperative scores (P < 0.05).
CONCLUSIONS: Vestibular schwannoma patients with disabling vertigo, experience significant reduced quality of life when compared with a healthy Dutch population. Translabyrinthine tumour removal significantly improved the patients' quality of life. Surgical treatment should be considered in patients with small- or medium-sized tumours and persisting disabling vertigo resulting in a poor quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 17550503     DOI: 10.1111/j.1365-2273.2007.01427.x

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  7 in total

1.  Patient quality of life after vestibular schwannoma removal: possibilities and limits to measuring different domains of patients' wellbeing.

Authors:  Julia Kristin; Marcel Fabian Glaas; Jörg Schipper; Thomas Klenzner; Katrin Eysel-Gosepath; Philipp Jansen; Matthias Franz; Ralf Schäfer
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-06-08       Impact factor: 2.503

2.  Vestibular schwannoma in patients with sudden sensorineural hearing loss.

Authors:  Jong Dae Lee; Byung Don Lee; Sun Chul Hwang
Journal:  Skull Base       Date:  2011-03

Review 3.  Management of vestibular schwannoma: focus on vertigo.

Authors:  Manisha Dayal; Angelica Perez-Andujar; Cynthia Chuang; Andrew T Parsa; Igor J Barani
Journal:  CNS Oncol       Date:  2013-01

4.  Vertigo in Vestibular Schwannoma Patients Due to Other Pathologies.

Authors:  Ronald Sahyouni; Omid Moshtaghi; Yarah M Haidar; Hossein Mahboubi; Afsheen Moshtaghi; Harrison W Lin; Hamid R Djalilian
Journal:  Otol Neurotol       Date:  2017-12       Impact factor: 2.311

5.  Auditory brainstem response prior to MRI compared to standalone MRI in the detection of vestibular schwannoma: A modelling study.

Authors:  Stan R W Wijn; Mayke A Hentschel; Andy J Beynon; Henricus P M Kunst; Maroeska M Rovers
Journal:  Clin Otolaryngol       Date:  2021-11-24       Impact factor: 2.729

6.  In search of the most cost-effective monitoring strategy for vestibular schwannoma: A decision analytical modelling study.

Authors:  Mirre Scholte; Mayke A Hentschel; Gerjon Hannink; Henricus P M Kunst; Stefan C Steens; Maroeska M Rovers; Janneke P C Grutters
Journal:  Clin Otolaryngol       Date:  2019-04-11       Impact factor: 2.597

7.  Quality of Life After Vestibular Schwannoma Surgery: A Question of Perspective.

Authors:  Miriam Bender; Marcos Tatagiba; Alireza Gharabaghi
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.